Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia
This study was withdrawn before enrollment.
In BostonThis study has finished and is no longer accepting participants.
In New HavenGlyT-1 Inhibitor Treatment for Refractory Schizophrenia and Its Effects on NMDA Modulation
This study has finished and is no longer accepting participants.
In Taichung
Cognitive Remediation of Executive Dysfunction - Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia
This study has finished and is no longer accepting participants.
In ReinsvollComparative Study of Recommended Treatment for Schizophrenia Guideline Treatment vs Treatment as Usual in Child Psychiatric Hospital: Effect on Adherence, Efficacy on Symptoms, and Global Function
This study has finished and is no longer accepting participants.
Location not clearly listed
Study on the Links Between Action and Perception in Schizophrenia, " Have a Good Grasp of the World "
This study has finished and is no longer accepting participants.
In Saint-Etienne
A Randomized, Double-blind Sham-controlled Trial of High Frequency rTMS for Cognitive Impairments in Chronic Schizophrenia Patients
This study has finished and is no longer accepting participants.
Location not clearly listedA Research on High-Definition Transcranial Direct Current Stimulation as a Treatment of Negative Symptoms in Patients With Schizophrenia
This study ended early.
In ShanghaiHigh-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms
This study has finished and is no longer accepting participants.
Multiple locations, including AugustaThis study has finished and is no longer accepting participants.
Multiple locations, including HelsinkiCardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers compared huperzine 0.2 mg BID, huperzine 0.4 mg BID, huperzine 0.8 mg BID and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
This study has finished and is no longer accepting participants.
In New HavenWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.